Loading...

Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine

Patients with pancreatic ductal adenocarcinoma (PDA) have a poor prognosis—in spite of new treatments, approximately 7% survive for 5 years. Although there have been advances in systemic, primarily cytotoxic, therapies, it has been a challenge to treat patients with PDA using targeted therapies. Seq...

Full description

Saved in:
Bibliographic Details
Published in:Gastroenterology
Main Authors: Knudsen, Erik S., O’Reilly, Eileen M., Brody, Jonathan R., Witkiewicz, Agnieszka K.
Format: Artigo
Language:Inglês
Published: 2015
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5010785/
https://ncbi.nlm.nih.gov/pubmed/26385075
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1053/j.gastro.2015.08.056
Tags: Add Tag
No Tags, Be the first to tag this record!